Journal
RESPIROLOGY
Volume 17, Issue 3, Pages 422-431Publisher
WILEY
DOI: 10.1111/j.1440-1843.2011.02118.x
Keywords
cardiovascular disease; chronic obstructive pulmonary disease; clinical epidemiology; emphysema; inflammation
Categories
Funding
- Boehringer Ingelheim
- Schering-Plough
- Pfizer
- Nycomed
- Menarini Industrie Farmaceutiche
- Chiesi
- GSK
- MSD
- Roche
- AstraZeneca
- Novartis
- Sigma-Tau
- Italian Ministry for University and Research
- Italian Ministry of Health
Ask authors/readers for more resources
Chronic obstructive pulmonary disease (COPD) and coronary artery disease (CAD) are global epidemics that incur significant morbidity and mortality. These diseases are frequently found in combination, and they can also be found independent of the common causal factors, primarily smoking. Both conditions are systemic disorders with overlapping mechanisms and pathophysiologic processes. CAD has a strong effect on the severity and prognosis of COPD and vice versa, including acute exacerbations. Even the most recent practical clinical recommendations driven by Clinical Practice Guidelines still focus on one disease at a time, and do not provide advice for the management of patients with associated chronic conditions. COPD should be approached in a more comprehensive manner, including the treatment of cardiac comorbidities, particularly CAD. To focus treatment on these comorbidities might modify the natural course of the disease in patients with COPD who may not find relief from treatment of COPD alone.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available